Please assess the completion status of the following clinical trial:

Trial Title: Surgical Treatment of Peri-implantitis With and Without Systemically Adjunctive Antibiotics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female ≥18-65 year~2. Patients who has been referred by a general dentist to a specialist clinic in periodontology for treatment of peri-implantitis.~3. Having sign of peri-implantitis around at least one osseointegrated dental implant that has been in function for ≥ one year~4. Peri-implantitis is diagnosed when; PPD of ≥ 6mm can be found at a dental implant in association with BOP and/or suppuration together with the loss of marginal alveolar bone of more than 2 mm detected on intraoral radiographs (giving radiographic exposure of at least ≥ 3 fixture threads).~5. Partially or completely edentulous subjects with healthy or treated periodontal conditions enrolled in a regular supportive program.~6. Full-Mouth Plaque Score (FMPS) ≤ 25~7. Signed informed consent~Exclusion Criteria:~1. Known allergy to amoxicillin, penicillin (PcV), metronidazole or betalactamic~2. Contraindication for dental surgical treatment (i.e. immunocompromised, uncontrolled DM (B-GHb-A1C 8-9 %, 64-75 mmol/mol), osteoporosis, I.V bisphosphonate treatment due to malignancy, pregnant and lactating women).~3. Incapability to perform basal oral hygiene measures due to physical or mental disorders.~4. Received systemic antimicrobial therapy in the past three months.~5. Currently on allopurinol, digoxin, disulfiram, lithium, busulfan, 5-fluorouracil, methotrexate, phenytoin, cyclosporine and warfarin.~6. Known severe chronic peripheral or central disease of the nervous system~7. Known alcohol abuse~8. Known hepatic encephalopathy~9. Known lactose intolerance, galactose intolerance~10. Untreated periodontal condition.~11. Implant showing sign of mobility.~12. Implants with bone loss exceeding 2/3 of the length of the implant or implants with bone loss beyond any transverse openings in hollow implants.~13. Any medical condition or on any concomitant medication that, in the opinion of the investigator, might interfere with the evaluation of the study objectives or jeopardize patient safety~Patients with xerostomia or having slow bowel motion will be excluded from the group of patients providing salivary and fecal samples.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: EXPERIMENTAL): Patients with periimplantitis undergoing surgical treatment with will receive placebo three times daily (TID)
- amoxicillin + metronidazole (Type: ACTIVE_COMPARATOR): Patients with periimplantitis undergoing surgical treatment with amoxicillin (500 mg TID) + metronidazole (400 mg TID) for 7 days
- phenoxymetylpencillin + metronidazol (Type: ACTIVE_COMPARATOR): Patients with periimplantitis undergoing surgical treatment with phenoxymetylpencillin, (800mg×2 TID) + metronidazol (400 mg TID) for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).